Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
Abstract
:Simple Summary
Abstract
1. Introduction
1.1. Cancer Immunotherapy and the Tumor Microenvironment (TME)
1.2. The Dual Effect of Adrenaline and Noradrenaline
1.3. βAR Signaling and the Impact on Cancer Cells
1.4. βAR Signaling and the Immune System
1.5. Mechanism of AR Signaling in the Context of Exercise Oncology
1.6. β-Blockers and Exercise in Cancer Treatment
2. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Conflicts of Interest
References
- World Health Organization. Global Recommendations on Physical Activity for Health; WHO Press: Geneva, Switzerland, 2010; Volume 7, ISBN 978-92-4-159-997-9. [Google Scholar]
- Guthold, R.; Stevens, G.A.; Riley, L.M.; Bull, F.C. Worldwide trends in insufficient physical activity from 2001 to 2016: A pooled analysis of 358 population-based surveys with 1·9 million participants. Lancet Glob. Health 2018, 6, e1077–e1086. [Google Scholar] [CrossRef] [Green Version]
- Lee, I.M.; Shiroma, E.J.; Lobelo, F.; Puska, P.; Blair, S.N.; Katzmarzyk, P.T.; Alkandari, J.R.; Andersen, L.B.; Bauman, A.E.; Brownson, R.C.; et al. Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of disease and life expectancy. Lancet 2012, 380, 219–229. [Google Scholar] [CrossRef]
- Moore, S.C.; Lee, I.-M.; Weiderpass, E.; Campbell, P.T.; Sampson, J.N.; Kitahara, C.M.; Keadle, S.K.; Arem, H.; Berrington de Gonzalez, A.; Hartge, P. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern. Med. 2016, 176, 816–825. [Google Scholar] [CrossRef] [PubMed]
- Wolin, K.Y.; Yan, Y.; Colditz, G.A.; Lee, I.M. Physical activity and colon cancer prevention: A meta-analysis. Br. J. Cancer 2009, 100, 611–616. [Google Scholar] [CrossRef] [PubMed]
- Lee, I.M.; Paffenbarger, R.S.; Hsieh, C.C. Physical activity and risk of developing colorectal cancer among college alumni. J. Natl. Cancer Inst. 1991, 83, 1324–1329. [Google Scholar] [CrossRef]
- Shaw, E.; Farris, M.S.; Stone, C.R.; Derksen, J.W.G.; Johnson, R.; Hilsden, R.J.; Friedenreich, C.M.; Brenner, D.R. Effects of physical activity on colorectal cancer risk among family history and body mass index subgroups: A systematic review and meta-analysis. BMC Cancer 2018, 18, 71. [Google Scholar] [CrossRef]
- Howard, R.A.; Leitzmann, M.F.; Linet, M.S.; Freedman, D.M. Physical activity and breast cancer risk among pre- and postmenopausal women in the, U.S. Radiologic Technologists cohort. Cancer Causes Control. 2009, 20, 323–333. [Google Scholar] [CrossRef] [Green Version]
- Steindorf, K.; Ritte, R.; Eomois, P.P.; Lukanova, A.; Tjonneland, A.; Johnsen, N.F.; Overvad, K.; Østergaard, J.N.; Clavel-Chapelon, F.; Fournier, A.; et al. Physical activity and risk of breast cancer overall and by hormone receptor status: The European prospective investigation into cancer and nutrition. Int. J. Cancer 2013, 132, 1667–1678. [Google Scholar] [CrossRef] [Green Version]
- Irwin, M.L.; Smith, A.W.; McTiernan, A.; Ballard-Barbash, R.; Cronin, K.; Gilliland, F.D.; Baumgartner, R.N.; Baumgartner, K.B.; Bernstein, L. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: The health, eating, activity, and lifestyle study. J. Clin. Oncol. 2008, 26, 3958–3964. [Google Scholar] [CrossRef]
- Holmes, M.D.; Chen, W.Y.; Feskanich, D.; Kroenke, C.H.; Colditz, G.A. Physical activity and survival after breast cancer diagnosis. JAMA 2005, 293, 2479–2486. [Google Scholar] [CrossRef] [Green Version]
- Ballard-Barbash, R.; Friedenreich, C.M.; Courneya, K.S.; Siddiqi, S.M.; McTiernan, A.; Alfano, C.M. Physical activity, biomarkers, and disease outcomes in cancer survivors: A systematic review. J. Natl. Cancer Inst. 2012, 104, 815–840. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Richman, E.L.; Kenfield, S.A.; Stampfer, M.J.; Paciorek, A.; Carroll, P.R.; Chan, J.M. Physical activity after diagnosis and risk of prostate cancer progression: Data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011, 71, 3889–3895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mravec, B.; Tibensky, M.; Horvathova, L. Stress and cancer. Part II: Therapeutic implications for oncology. J. Neuroimmunol. 2020, 346, 577312. [Google Scholar] [CrossRef] [PubMed]
- Dumas, J.-F.; Brisson, L. Interaction between adipose tissue and cancer cells: Role for cancer progression. Cancer Metastasis Rev. 2020. [Google Scholar] [CrossRef]
- Drijvers, J.M.; Sharpe, A.H.; Haigis, M.C. The effects of age and systemic metabolism on anti-tumor T cell responses. eLife 2020, 9, 1–29. [Google Scholar] [CrossRef]
- Turner, J.E.; Brum, P.C. Does Regular Exercise Counter T Cell Immunosenescence Reducing the Risk of Developing Cancer and Promoting Successful Treatment of Malignancies? Oxid. Med. Cell. Longev. 2017, 2017. [Google Scholar] [CrossRef]
- Todoric, J.; Antonucci, L.; Karin, M. Targeting inflammation in cancer prevention and therapy. Cancer Prev. Res. 2016, 9, 895–905. [Google Scholar] [CrossRef] [Green Version]
- Taves, M.D.; Ashwell, J.D. Glucocorticoids in T cell development, differentiation and function. Nat. Rev. Immunol. 2020, 1. [Google Scholar] [CrossRef]
- Shimba, A.; Ikuta, K. Control of immunity by glucocorticoids in health and disease. Semin. Immunopathol. 2020, 42, 669–680. [Google Scholar] [CrossRef]
- Ahmad, A.; Uddin, S.; Steinhoff, M. CAR-T cell therapies: An overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large b-cell lymphomas. Int. J. Mol. Sci. 2020, 21, 3906. [Google Scholar] [CrossRef]
- Alsaab, H.O.; Sau, S.; Alzhrani, R.; Tatiparti, K.; Bhise, K.; Kashaw, S.K.; Iyer, A.K. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front. Pharmacol. 2017, 8, 561. [Google Scholar] [CrossRef] [PubMed]
- Nasser, N.J.; Gorenberg, M.; Agbarya, A. First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals 2020, 13, 373. [Google Scholar] [CrossRef] [PubMed]
- Oliveira, L.J.C.; Gongora, A.B.L.; Jardim, D.L.F. Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. Curr. Oncol. Rep. 2020, 22, 70. [Google Scholar] [CrossRef] [PubMed]
- Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T.S.; et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348, 124–128. [Google Scholar] [CrossRef] [Green Version]
- Goodman, A.M.; Sokol, E.S.; Frampton, G.M.; Lippman, S.M.; Kurzrock, R. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol. Res. 2019, 7, 1570–1573. [Google Scholar] [CrossRef] [Green Version]
- Clark, W.H. Tumour progression and the nature of cancer. Br. J. Cancer 1991, 64, 631–644. [Google Scholar] [CrossRef] [Green Version]
- Galon, J.; Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 2019, 18, 197–218. [Google Scholar] [CrossRef]
- Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pagès, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960–1964. [Google Scholar] [CrossRef] [Green Version]
- Angell, H.K.; Bruni, D.; Barrett, J.C.; Herbst, R.; Galon, J. The Immunoscore: Colon Cancer and Beyond. Clin. Cancer Res. 2020, 26, 332–339. [Google Scholar] [CrossRef] [Green Version]
- de Olza, M.O.; Rodrigo, B.N.; Zimmermann, S.; Coukos, G. Turning up the heat on non-immunoreactive tumours: Opportunities for clinical development. Lancet Oncol. 2020, 21, e419–e430. [Google Scholar] [CrossRef]
- Pedersen, L.; Idorn, M.; Olofsson, G.H.; Lauenborg, B.; Nookaew, I.; Hansen, R.H.; Johannesen, H.H.; Becker, J.C.; Pedersen, K.S.; Dethlefsen, C.; et al. Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. Cell Metab. 2016, 23, 554–562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cole, S.W.; Sood, A.K. Molecular pathways: Beta-adrenergic signaling in cancer. Clin. Cancer Res. 2012, 18, 1201–1206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baker, J.G. The selectivity of β-adrenoceptor agonists at human β 1-, β 2- and β 3-adrenoceptors: RESEARCH PAPER. Br. J. Pharmacol. 2010, 160, 1048–1061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rooney, B.V.; Bigley, A.B.; LaVoy, E.C.; Laughlin, M.; Pedlar, C.; Simpson, R.J. Lymphocytes and monocytes egress peripheral blood within minutes after cessation of steady state exercise: A detailed temporal analysis of leukocyte extravasation. Physiol. Behav. 2018, 194, 260–267. [Google Scholar] [CrossRef] [Green Version]
- Dhabhar, F.S. The short-term stress response—Mother nature’s mechanism for enhancing protection and performance under conditions of threat, challenge, and opportunity. Front. Neuroendocrinol. 2018, 49, 175–192. [Google Scholar] [CrossRef]
- Bucsek, M.J.; Qiao, G.; MacDonald, C.R.; Giridharan, T.; Evans, L.; Niedzwecki, B.; Liu, H.; Kokolus, K.M.; Eng, J.W.L.; Messmer, M.N.; et al. β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res. 2017, 77, 5639–5651. [Google Scholar] [CrossRef] [Green Version]
- Maisel, A.S.; Fowler, P.; Rearden, A.; Motulsky, H.J.; Michel, M.C. A new method for isolation of human lymphocyte subsets reveals differential regulation of β-adrenergic receptors by terbutaline treatment. Clin. Pharmacol. Ther. 1989, 46, 429–439. [Google Scholar] [CrossRef]
- Wahle, M.; Stachetzki, U.; Krause, A.; Pierer, M.; Häntzschel, H.; Baerwald, C.G.O. Regulation of beta2-adrenergic receptors on CD4 and CD8 positive lymphocytes by cytokines in vitro. Cytokine 2001, 16, 205–209. [Google Scholar] [CrossRef]
- Brodde, O.E.; Brinkmann, M.; Schemuth, R.; O’Hara, N.; Daul, A. Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen. J. Clin. Investig. 1985, 76, 1096–1101. [Google Scholar] [CrossRef] [Green Version]
- Johnson, M. Molecular mechanisms of β2-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 2006, 117, 18–24. [Google Scholar] [CrossRef]
- Yu, B.H.; Dimsdale, J.E.; Mills, P.J. Psychological states and lymphocyte β-Adrenergic receptor responsiveness. Neuropsychopharmacology 1999, 21, 147–152. [Google Scholar] [CrossRef]
- Madden, K.S.; Szpunar, M.J.; Brown, E.B. β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines. Breast Cancer Res. Treat. 2011, 130, 747–758. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Powe, D.G.; Voss, M.J.; Zänker, K.S.; Habashy, H.O.; Green, A.R.; Ellis, I.O.; Entschladen, F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010, 1, 628–638. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, H.; Liao, Z.; Zhuang, Y.; Liu, Y.; Levy, L.B.; Xu, T.; Yusuf, S.W.; Gomez, D.R. Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy. Clin. Lung Cancer 2015, 16, 128–136. [Google Scholar] [CrossRef] [PubMed]
- Oh, M.S.; Guzner, A.; Wainwright, D.A.; Mohindra, N.A.; Chae, Y.K.; Behdad, A.; Villaflor, V.M. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clin. Lung Cancer 2020, 1–6. [Google Scholar] [CrossRef]
- Gandhi, S.; Pandey, M.R.; Attwood, K.; Ji, W.; Witkiewicz, A.K.; Knudsen, E.S.; Allen, C.; Tario, J.D.; Wallace, P.K.; Cedeno, C.D.; et al. Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clin. Cancer Res. 2020. [Google Scholar] [CrossRef]
- De Giorgi, V.; Grazzini, M.; Benemei, S.; Marchionni, N.; Botteri, E.; Pennacchioli, E.; Geppetti, P.; Gandini, S. Propranolol for off-label treatment of patients with melanoma: Results from a cohort study. JAMA Oncol. 2018, 4, 2018–2021. [Google Scholar] [CrossRef]
- Hojman, P.; Gehl, J.; Christensen, J.F.; Pedersen, B.K. Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. Cell Metab. 2018, 27, 10–21. [Google Scholar] [CrossRef] [Green Version]
- Rains, S.L.; Amaya, C.N.; Bryan, B.A. Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience 2017, 4, 95–105. [Google Scholar] [CrossRef] [Green Version]
- Cole, S.W.; Nagaraja, A.S.; Lutgendorf, S.K.; Green, P.A.; Sood, A.K. Sympathetic nervous system regulation of the tumour microenvironment. Nat. Rev. Cancer 2015, 15, 563–572. [Google Scholar] [CrossRef] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mravec, B.; Horvathova, L.; Hunakova, L. Neurobiology of Cancer: The Role of β-Adrenergic Receptor Signaling in Various Tumor Environments. Int. J. Mol. Sci. 2020, 21, 7958. [Google Scholar] [CrossRef] [PubMed]
- Koelwyn, G.J.; Quail, D.F.; Zhang, X.; White, R.M.; Jones, L.W. Exercise-dependent regulation of the tumour microenvironment. Nat. Publ. Gr. 2017, 17, 620–632. [Google Scholar] [CrossRef] [PubMed]
- Walker, A.K.; Martelli, D.; Ziegler, A.I.; Lambert, G.W.; Phillips, S.E.; Hill, S.J.; McAllen, R.M.; Sloan, E.K. Circulating epinephrine is not required for chronic stress to enhance metastasis. Psychoneuroendocrinology 2019, 99, 191–195. [Google Scholar] [CrossRef]
- Eng, J.W.L.; Reed, C.B.; Kokolus, K.M.; Pitoniak, R.; Utley, A.; Bucsek, M.J.; Ma, W.W.; Repasky, E.A.; Hylander, B.L. Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation. Nat. Commun. 2015, 6, 6426. [Google Scholar] [CrossRef] [Green Version]
- Kokolus, K.M.; Capitano, M.L.; Lee, C.-T.; Eng, J.W.L.; Waight, J.D.; Hylander, B.L.; Sexton, S.; Hong, C.-C.; Gordon, C.J.; Abrams, S.I.; et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc. Natl. Acad. Sci. USA 2013, 110, 20176–20181. [Google Scholar] [CrossRef] [Green Version]
- Perego, M.; Tyurin, V.A.; Tyurina, Y.Y.; Yellets, J.; Nacarelli, T.; Lin, C.; Nefedova, Y.; Kossenkov, A.; Liu, Q.; Sreedhar, S. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci. Transl. Med. 2020, 12, 5817. [Google Scholar] [CrossRef]
- Kokolus, K.M.; Zhang, Y.; Sivik, J.M.; Schmeck, C.; Zhu, J.; Repasky, E.A.; Drabick, J.J.; Schell, T.D. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology 2018, 7, e1405205. [Google Scholar] [CrossRef] [Green Version]
- Arnold, J.; Barcena de Arellano, M.L.; Rüster, C.; Vercellino, G.F.; Chiantera, V.; Schneider, A.; Mechsner, S. Imbalance between sympathetic and sensory innervation in peritoneal endometriosis. Brain Behav. Immun. 2012, 26, 132–141. [Google Scholar] [CrossRef]
- Kurozumi, S.; Kaira, K.; Matsumoto, H.; Hirakata, T.; Yokobori, T.; Inoue, K.; Horiguchi, J.; Katayama, A.; Koshi, H.; Shimizu, A. β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. Breast Cancer Res. Treat 2019, 177, 603–610. [Google Scholar] [CrossRef]
- Lamichhane, R.; Liu, J.J.; Pljevaljcic, G.; White, K.L.; Van Der Schans, E.; Katritch, V.; Stevens, R.C.; Wüthrich, K.; Millar, D.P. Single-molecule view of basal activity and activation mechanisms of the G protein-coupled receptor β2 AR. Proc. Natl. Acad. Sci. USA 2015, 112, 14254–14259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hassan, S.; Karpova, Y.; Baiz, D.; Yancey, D.; Pullikuth, A.; Flores, A.; Register, T.; Cline, J.M.; D’agostino, R.; Danial, N. Behavioral stress accelerates prostate cancer development in mice. J. Clin. Investig. 2013, 123, 874–886. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sloan, E.K.; Priceman, S.J.; Cox, B.F.; Yu, S.; Pimentel, M.A.; Tangkanangnukul, V.; Arevalo, J.M.G.; Morizono, K.; Karanikolas, B.D.W.; Wu, L.; et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010, 70, 7042–7052. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lamkin, D.M.; Sloan, E.K.; Patel, A.J.; Chiang, B.S.; Pimentel, M.A.; Ma, J.C.Y.; Arevalo, J.M.; Morizono, K.; Cole, S.W. Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling. Brain Behav. Immun. 2012, 26, 635–641. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rivero, E.M.; Piñero, C.P.; Gargiulo, L.; Entschladen, F.; Zänker, K.; Bruzzone, A.; Lüthy, I.A. The β 2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and Metastasis of the Human Breast Cancer MDA-MB- 231 Cell Line. Curr. Cancer Drug Targets 2017, 17, 756–766. [Google Scholar] [CrossRef]
- Hara, M.R.; Kovacs, J.J.; Whalen, E.J.; Rajagopal, S.; Strachan, R.T.; Grant, W.; Towers, A.J.; Williams, B.; Lam, C.M.; Xiao, K.; et al. A stress response pathway regulates DNA damage through β2- adrenoreceptors and β-arrestin-1. Nature 2011, 477, 349–353. [Google Scholar] [CrossRef] [Green Version]
- Chen, H.; Zhang, W.; Cheng, X.; Guo, L.; Xie, S.; Ma, Y.; Guo, N.; Shi, M. β2-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells. Cancer Sci. 2017, 108, 1310–1317. [Google Scholar] [CrossRef] [Green Version]
- Graff, R.M.; Kunz, H.E.; Agha, N.H.; Baker, F.L.; Laughlin, M.; Bigley, A.B.; Markofski, M.M.; LaVoy, E.C.; Katsanis, E.; Bond, R.A.; et al. β2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain Behav. Immun. 2018, 74, 143–153. [Google Scholar] [CrossRef]
- LaVoy, E.C.; Hussain, M.; Reed, J.; Kunz, H.; Pistillo, M.; Bigley, A.B.; Simpson, R.J. T-cell redeployment and intracellular cytokine expression following exercise: Effects of exercise intensity and cytomegalovirus infection. Physiol. Rep. 2017, 5. [Google Scholar] [CrossRef]
- Bay, M.L.; Heywood, S.; Wedell-Neergaard, A.S.; Schauer, T.; Lehrskov, L.L.; Christensen, R.H.; Legård, G.E.; Jensen, P.Ø.; Krogh-Madsen, R.; Ellingsgaard, H. Human immune cell mobilization during exercise: Effect of IL-6 receptor blockade. Exp. Physiol. 2020, 1–13. [Google Scholar] [CrossRef]
- Krüger, K.; Lechtermann, A.; Fobker, M.; Völker, K.; Mooren, F.C. Exercise-induced redistribution of T lymphocytes is regulated by adrenergic mechanisms. Brain Behav. Immun. 2008, 22, 324–338. [Google Scholar] [CrossRef] [PubMed]
- Dhabhar, F.S.; McEwen, B.S. Acute stress enhances while chronic stress suppresses cell-mediated immunity in vivo: A potential role for leukocyte trafficking. Brain Behav. Immun. 1997, 11, 286–306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baik, I.; Curhan, G.C.; Rimm, E.B.; Bendich, A.; Willett, W.C.; Fawzi, W.W. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch. Intern. Med. 2000, 160, 3082–3088. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Woods, J.A.; Keylock, K.T.; Lowder, T.; Vieira, V.J.; Zelkovich, W.; Dumich, S.; Colantuano, K.; Lyons, K.; Leifheit, K.; Cook, M.; et al. Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: The immune function intervention trial. J. Am. Geriatr. Soc. 2009, 57, 2183–2191. [Google Scholar] [CrossRef]
- Simpson, R.J.; Campbell, J.P.; Gleeson, M.; Krüger, K.; Nieman, D.C.; Pyne, D.B.; Turner, J.E.; Walsh, N.P. Can exercise affect immune function to increase susceptibility to infection? Exerc. Immunol. Rev. 2020, 26, 8–22. [Google Scholar]
- Swanson, M.A.; Lee, W.T.; Sanders, V.M. IFN-γ Production by Th1 Cells Generated from Naive CD4 + T Cells Exposed to Norepinephrine. J. Immunol. 2001, 166, 232–240. [Google Scholar] [CrossRef] [Green Version]
- Feldman, R.D.; Hunninghake, G.W.; McArdle, W.L. Beta-adrenergic-receptor-mediated suppression of interleukin 2 receptors in human lymphocytes. J. Immunol. 1987, 139, 3355–3359. [Google Scholar]
- Estrada, L.D.D.; Ağaç, D.; Farrar, J.D.D. Sympathetic neural signaling via the β2-adrenergic receptor suppresses T-cell receptor-mediated human and mouse CD8+T-cell effector function. Eur. J. Immunol. 2016, 46, 1948–1958. [Google Scholar] [CrossRef] [Green Version]
- Zalli, A.; Bosch, J.A.; Goodyear, O.; Riddell, N.; McGettrick, H.M.; Moss, P.; Wallace, G.R. Targeting ß2 adrenergic receptors regulate human T cell function directly and indirectly. Brain Behav. Immun. 2015, 45, 211–218. [Google Scholar] [CrossRef]
- Qiao, G.; Bucsek, M.J.J.; Winder, N.M.M.; Chen, M.; Giridharan, T.; Olejniczak, S.H.H.; Hylander, B.L.L.; Repasky, E.A.A. β-Adrenergic signaling blocks murine CD8+ T-cell metabolic reprogramming during activation: A mechanism for immunosuppression by adrenergic stress. Cancer Immunol. Immunother. 2019, 68, 11–22. [Google Scholar] [CrossRef] [Green Version]
- Theorell, J.; Gustavsson, A.-L.; Tesi, B.; Sigmundsson, K.; Ljunggren, H.-G.; Lundbäck, T.; Bryceson, Y.T. Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation. Cancer Immunol. Immunother. 2014, 63, 627–641. [Google Scholar] [CrossRef] [PubMed]
- Dokur, M.; Boyadjieva, N.; Sarkar, D.K. Catecholaminergic control of NK cell cytolytic activity regulatory factors in the spleen. J. Neuroimmunol. 2004, 151, 148–157. [Google Scholar] [CrossRef] [PubMed]
- Hellstrand, K.; Hermodsson, S.; Strannegård, O. Evidence for a beta-adrenoceptor-mediated regulation of human natural killer cells. J. Immunol. 1985, 134, 4095–4099. [Google Scholar] [PubMed]
- Pedersen, L.; Christensen, J.F.; Hojman, P. Effects of exercise on tumor physiology and metabolism. Cancer J. 2015, 21, 111–116. [Google Scholar] [CrossRef]
- Ashcraft, K.A.; Peace, R.M.; Betof, A.S.; Dewhirst, M.W.; Jones, L.W. Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data. Cancer Res. 2016, 76, 4032–4050. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hagar, A.; Wang, Z.; Koyama, S.; Serrano, J.A.; Melo, L.; Vargas, S.; Carpenter, R.; Foley, J. Endurance training slows breast tumor growth in mice by suppressing Treg cells recruitment to tumors. BMC Cancer 2019, 19, 536. [Google Scholar] [CrossRef] [Green Version]
- Wennerberg, E.; Lhuillier, C.; Rybstein, M.D.; Dannenberg, K.; Rudqvist, N.-P.; Koelwyn, G.J.; Jones, L.W.; Demaria, S. Exercise reduces immune suppression and breast cancer progression in a preclinical model. Oncotarget 2020, 11, 452–461. [Google Scholar] [CrossRef] [Green Version]
- Rundqvist, H.; Veliça, P.; Barbieri, L.; Gameiro, P.A.; Bargiela, D.; Gojkovic, M.; Mijwel, S.; Reitzner, S.M.; Wulliman, D.; Ahlstedt, E.; et al. Cytotoxic T-cells mediate exercise-induced reductions in tumor growth. eLife 2020, 9, 1–25. [Google Scholar] [CrossRef]
- Ozyurek, B.A.; Ozdemirel, T.S.; Ozden, S.B.; Erdogan, Y.; Kaplan, B.; Kaplan, T. Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR) in Lung Cancer Cases. Asian Pac. J. Cancer Prev. 2017, 18, 1417–1421. [Google Scholar] [CrossRef]
- Vetsika, E.-K.; Koinis, F.; Gioulbasani, M.; Aggouraki, D.; Koutoulaki, A.; Skalidaki, E.; Mavroudis, D.; Georgoulias, V.; Kotsakis, A. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J. Immunol. Res. 2014, 2014, 659294. [Google Scholar] [CrossRef]
- de Goeje, P.L.; Bezemer, K.; Heuvers, M.E.; Dingemans, A.-M.C.; Groen, H.J.; Smit, E.F.; Hoogsteden, H.C.; Hendriks, R.W.; Aerts, J.G.; Hegmans, J.P. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. Oncoimmunology 2015, 4, e1014242. [Google Scholar] [CrossRef] [Green Version]
- Youn, J.I.; Park, S.M.; Park, S.; Kim, G.; Lee, H.J.; Son, J.; Hong, M.H.; Ghaderpour, A.; Baik, B.; Islam, J.; et al. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Sci. Rep. 2020, 10, 1–7. [Google Scholar] [CrossRef]
- Stankovic, B.; Bjørhovde, H.A.K.; Skarshaug, R.; Aamodt, H.; Frafjord, A.; Müller, E.; Hammarström, C.; Beraki, K.; Bækkevold, E.S.; Woldbæk, P.R.; et al. Immune Cell Composition in Human Non-small Cell Lung Cancer. Front. Immunol. 2018, 9, 3101. [Google Scholar] [CrossRef] [Green Version]
- Coelho, M.; Soares-Silva, C.; Brandão, D.; Marino, F.; Cosentino, M.; Ribeiro, L. β-Adrenergic modulation of cancer cell proliferation: Available evidence and clinical perspectives. J. Cancer Res. Clin. Oncol. 2017, 143, 275–291. [Google Scholar] [CrossRef]
- Watkins, J.L.; Thaker, P.H.; Nick, A.M.; Ramondetta, L.M.; Kumar, S.; Urbauer, D.L.; Matsuo, K.; Squires, K.C.; Coleman, R.L.; Lutgendorf, S.K.; et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 2015, 121, 3444–3451. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jensen, A.W.P.; Carnaz Simões, A.M.; thor Straten, P.; Holmen Olofsson, G. Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe? Cancers 2021, 13, 394. https://doi.org/10.3390/cancers13030394
Jensen AWP, Carnaz Simões AM, thor Straten P, Holmen Olofsson G. Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe? Cancers. 2021; 13(3):394. https://doi.org/10.3390/cancers13030394
Chicago/Turabian StyleJensen, Agnete Witness Praest, Ana Micaela Carnaz Simões, Per thor Straten, and Gitte Holmen Olofsson. 2021. "Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?" Cancers 13, no. 3: 394. https://doi.org/10.3390/cancers13030394